Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results

Susan Bal, Myo Htut, Jesús G. Berdeja, Larry D Anderson, Jr., Adriana Rossi, Tara Gregory, Thomas G Martin, Luciano J. Costa, Hongxiang Hu, Jinjie Chen, Chaoqun Mei, Naomey Sarkis, Alok Shrestha, Safiyyah Ziyad, Wei-Ming Kao, Allison J Kaeding, Michael R. Burgess, Omar Nadeem

Blood (2024) 144 (Supplement 1): 2069.

https://doi.org/10.1182/blood-2024-203279

Published: 2024

Journal Articles

Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)

Blood (2024) 144 (Supplement 1): 922.

https://doi.org/10.1182/blood-2024-201356

Published: 2024

Journal Articles

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Blood (2023) 142 (Supplement 1): 219.

https://doi.org/10.1182/blood-2023-181857

Published: 2023

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Blood (2023) 142 (Supplement 1): 2011.

https://doi.org/10.1182/blood-2023-180013

Published: 2023

Journal Articles

Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Isaac W. Boss, Ethan Thompson, Allison M. Gaudy, Minh Diem Vu, Colin D. Godwin, Michael R. Burgess, Sandy W. Wong, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 7116–7117.

https://doi.org/10.1182/blood-2022-163192

Published: 2022

Journal Articles

Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)

Danny V Jeyaraju, Maryam Alapa, Aimee O'Donohue, Ross La Motte-Mohs, Isaac W. Boss, Patrick Hagner, Michael Pourdehnad, Michael R. Burgess, William E. Pierceall, Anjan Thakurta

Blood (2022) 140 (Supplement 1): 7070–7071.

https://doi.org/10.1182/blood-2022-157927

Published: 2022

Journal Articles

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Susan Bal, M. Hakan Kocoglu, Omar Nadeem, Myo Htut, Tara Gregory, Larry D. Anderson, Jr., Luciano J. Costa, Tonia J. Buchholz, Safiyyah Ziyad, Meng Li, Yanping Chen, Allison J. Kaeding, Michael R. Burgess, Kristen Hege, Jesus Berdeja

Blood (2022) 140 (Supplement 1): 883–885.

https://doi.org/10.1182/blood-2022-162395

Published: 2022

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Blood (2022) 140 (Supplement 1): 400–402.

https://doi.org/10.1182/blood-2022-159009

Published: 2022

Journal Articles

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Luciano J. Costa, Shaji K Kumar, Shebli Atrash, Michaela Liedtke, Gurbakhash Kaur, Benjamin A. Derman, P. Leif Bergsagel, Sham Mailankody, Philip L. McCarthy, Josiana Limones, Yanping Chen, Sharmila Das, Jerill Thorpe, Jonathan Cacciatore, Garnet Navarro, Ashley K Koegel, Michael R. Burgess, Kristen Hege, Shambavi Richard

Blood (2022) 140 (Supplement 1): 1360–1362.

https://doi.org/10.1182/blood-2022-160038

Published: 2022

Journal Articles

Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Paolo Strati, Eliza Hawkes, Nilanjan Ghosh, Joseph M. Tuscano, Quincy Chu, Mary Ann Anderson, Amar Patel, Michael R. Burgess, Kristen Hege, Sapna Chhagan, Sarandeep Boyanapalli, Tracey Day, Frank Shen, Amitkumar Mehta

Blood (2021) 138 (Supplement 1): 2493.

https://doi.org/10.1182/blood-2021-147292

Published: 2021

Journal Articles

Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML

Benjamin J. Huang, MD, Xinyue Wang, BA, Max Harris, BA, Anica Wandler, PhD, Eugene Hwang, BA, Michael R. Burgess, MD PhD, Qing Li, MD PhD, Paul Severson, PhD, Ben Powell, PhD, Edward A. Kolb, MD, Soheil Meshinchi, MDPhD, Barry S Taylor, PhD, Gideon Bollag, PhD, Kevin M. Shannon, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-142921

Published: 2020

Journal Articles

A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

Amer M. Zeidan, MBBS, MHS, Daniel J. DeAngelo, MD PhD, Jeanne M. Palmer, Christopher S. Seet, MD PhD, Martin S. Tallman, MD, Xin Wei, PhD, Ying Fei Li, PhD, Nanette Hock, RN, MSN, Michael R. Burgess, Kristen Hege, Wendy Stock, MD

Blood (2019) 134 (Supplement_1): 1320.

https://doi.org/10.1182/blood-2019-125363

Published: 2019

Journal Articles

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

Luciano J. Costa, MD PhD, Sandy W. Wong, Arancha Bermúdez, Javier de la Rubia, María-Victoria Mateos, Enrique M. Ocio, Paula Rodríguez-Otero, Jesús San-Miguel, Shaoyi Li, Rafael Sarmiento, Pilar Lardelli, Allison Gaudy, Isaac Boss, Lisa M. Kelly, Michael R. Burgess, Kristen Hege, William I. Bensinger

Blood (2019) 134 (Supplement_1): 143.

https://doi.org/10.1182/blood-2019-122895

Published: 2019

Journal Articles

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Pau Abrisqueta, MD PhD, Juan-Manuel Sancho, MD PhD, Raul Cordoba, MD PhD, Daniel O. Persky, MD, Charalambos Andreadis, MD MSCE, Scott F. Huntington, MD MPH, Cecilia Carpio, MD, Daniel Morillo Giles, MD, Xin Wei, PhD, Ying Fei Li, PhD, Marlene Zuraek, MD, Michael R. Burgess, Kristen Hege, Alejandro Martín, MD PhD

Blood (2019) 134 (Supplement_1): 4089.

https://doi.org/10.1182/blood-2019-125310

Published: 2019

Journal Articles

Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS

Ningfei An, Saira Khan, Molly K. Imgruet, Sandeep K. Gurbuxani, Stephanie N. Konecki, Michael R. Burgess, Megan E. McNerney

Blood (2018) 131 (24): 2682–2697.

https://doi.org/10.1182/blood-2017-10-810028

Published: 2018

Includes: Supplemental data

Journal Articles

Deficiency of Cux1 , Encoded on Human Chromosome 7q, Causes Aberrant Hematopoietic Stem Cell Function and Spontaneous Myeloproliferative Disease in Mice

Ningfei An, PhD, Saira Khan, Molly Imgruet, Sandeep Gurbuxani, MBBS, PhD, Michael R. Burgess, MD PhD, Megan E. McNerney, MD PhD

Blood (2017) 130 (Supplement 1): 789.

https://doi.org/10.1182/blood.V130.Suppl_1.789.789

Published: 2017

Journal Articles

Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia

Alexandre Puissant, PhD, Nina Fenouille, PhD, Christopher F. Bassil, BA, Issam Ben-Sahra, PhD, Lina Benajiba, Gabriela Alexe, PhD, Azucena Ramos, Yana Pikman, MD, Michael R. Burgess, MD PhD, Qing Li, MD PhD, Frederic Luciano, PhD, Patrick Auberger, PhD, Ilene Galinsky, MSN, ANPc, Daniel J. DeAngelo, MD PhD, Richard M. Stone, MD, Archibald S. Perkins, MD PhD, Kevin Shannon, MD, Michael T. Hemann, PhD, Kimberly Stegmaier, MD

Blood (2016) 128 (22): 523.

https://doi.org/10.1182/blood.V128.22.523.523

Published: 2016

Journal Articles

Identification of CKMT1B As a New Target in EVI1-Positive AML

Alexandre Puissant, PhD, Nina Fenouille, PhD, Christopher F. Bassil, BA, Issam Ben-Sahra, PhD, Gabriela Alexe, PhD, Lina Benajiba, Azucena Ramos, Yana Pikman, MD, Michael R. Burgess, MD PhD, Ilene Galinsky, ANP, Daniel J. DeAngelo, MD PhD, Richard M. Stone, MD, Kevin Shannon, MD, Michael T. Hemann, PhD, Kimberly Stegmaier, MD

Blood (2015) 126 (23): 3674.

https://doi.org/10.1182/blood.V126.23.3674.3674

Published: 2015

Journal Articles

Preclinical efficacy of MEK inhibition in Nras -mutant AML

Michael R. Burgess, Eugene Hwang, Ari J. Firestone, Tannie Huang, Jin Xu, Johannes Zuber, Natacha Bohin, Tiffany Wen, Scott C. Kogan, Kevin M. Haigis, Deepak Sampath, Scott Lowe, Kevin Shannon, Qing Li

Blood (2014) 124 (26): 3947–3955.

https://doi.org/10.1182/blood-2014-05-574582

Published: 2014

Includes: Supplemental data

Journal Articles

Aberrant Hematopoietic Stem Cell Function in Mice Haploinsufficient for a 2 Mb Deletion of Chromosome 5A3 Syntenic to a Region of Human 7q22 Frequently Deleted in Myelodysplastic Syndromes

Jasmine C. Wong, PhD, Kelley Weinfurtner, BA, Pilar Alzamora, Scott C. Kogan, MD, Michael R. Burgess, MD PhD, Yan Zhang, PhD, Joy Nakitandwe, PhD, Jing Ma, PhD, Jinjun Cheng, MB, MS, Shann-Ching Chen, PhD, Johanna Flach, Damien Reynaud, PhD, Emmanuelle Passegue, PhD, James R Downing, MD, Kevin Shannon, MD

Blood (2014) 124 (21): 3247.

https://doi.org/10.1182/blood.V124.21.3247.3247

Published: 2014

NARROW

BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results

Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML

A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS

Deficiency of Cux1 , Encoded on Human Chromosome 7q, Causes Aberrant Hematopoietic Stem Cell Function and Spontaneous Myeloproliferative Disease in Mice

Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia

Identification of CKMT1B As a New Target in EVI1-Positive AML

Preclinical efficacy of MEK inhibition in Nras -mutant AML

Aberrant Hematopoietic Stem Cell Function in Mice Haploinsufficient for a 2 Mb Deletion of Chromosome 5A3 Syntenic to a Region of Human 7q22 Frequently Deleted in Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only